Integrating CROSS – style chemotherapy regime into higher doses of radiation for the radical treatment of localized oesophageal carcinoma in patien...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter S. Lim Pei
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors S. Lim Pei1, R. Kanani1, R. Mir2, M. Harrison2
  • 1Mount Vernon Cancer Centre, Northwood, United Kingdom, /
  • 2Mount Vernon Hospital, Northwood, United Kingdom, /


The CROSS group published data supporting the use of neoadjuvant chemoradiotherapy for oesophageal cancer in 2012, demonstrating good efficacy with an observed complete pathological response rate of 29% in surgical specimens. Given that this regimen has little toxicity and was generally well tolerated, we investigated the feasibility of integrating this regimen to the radical setting in patients who were of borderline fitness to receive radical chemo-radiotherapy with cisplatin.